Roth Capital Lowers Earnings Estimates for Journey Medical

Journey Medical Co. (NASDAQ:DERM - Free Report) - Stock analysts at Roth Capital reduced their Q2 2025 earnings per share estimates for Journey Medical in a report issued on Thursday, May 15th. Roth Capital analyst J. Wittes now expects that the company will post earnings of ($0.08) per share for the quarter, down from their prior estimate of ($0.02). The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. Roth Capital also issued estimates for Journey Medical's Q3 2025 earnings at $0.00 EPS, Q4 2025 earnings at $0.03 EPS and FY2025 earnings at ($0.23) EPS.

Journey Medical (NASDAQ:DERM - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.06. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%. The firm had revenue of $13.14 million during the quarter, compared to analysts' expectations of $12.05 million.

A number of other research firms have also recently issued reports on DERM. Industrial Alliance Securities set a $10.50 target price on Journey Medical in a research note on Thursday, March 27th. Alliance Global Partners reaffirmed a "buy" rating on shares of Journey Medical in a research report on Thursday, March 27th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Journey Medical presently has a consensus rating of "Buy" and a consensus target price of $9.88.

Journey Medical Stock Down 2.4%

NASDAQ:DERM opened at $6.93 on Monday. Journey Medical has a 1 year low of $3.20 and a 1 year high of $8.24. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81. The stock has a market cap of $160.11 million, a price-to-earnings ratio of -7.37 and a beta of 0.86. The stock has a 50-day moving average price of $6.44 and a two-hundred day moving average price of $5.42.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of DERM. Titleist Asset Management LLC raised its holdings in Journey Medical by 18.3% during the first quarter. Titleist Asset Management LLC now owns 12,900 shares of the company's stock worth $76,000 after acquiring an additional 2,000 shares in the last quarter. Cetera Investment Advisers raised its holdings in Journey Medical by 21.8% during the fourth quarter. Cetera Investment Advisers now owns 13,839 shares of the company's stock worth $54,000 after acquiring an additional 2,478 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its holdings in Journey Medical by 3.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 338,050 shares of the company's stock worth $1,994,000 after acquiring an additional 9,938 shares in the last quarter. Kovitz Investment Group Partners LLC raised its holdings in Journey Medical by 112.9% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company's stock worth $97,000 after acquiring an additional 13,105 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in Journey Medical during the fourth quarter worth about $80,000. 7.25% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Journey Medical

In other news, CEO Claude Maraoui sold 18,147 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $5.13, for a total transaction of $93,094.11. Following the completion of the transaction, the chief executive officer now directly owns 2,092,874 shares of the company's stock, valued at $10,736,443.62. This represents a 0.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 113,522 shares of company stock valued at $589,229 over the last three months. Company insiders own 15.03% of the company's stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.